RxDoctor Payments Data

Silvana Toscano, PA

Physician Assistant · Naples, FLNPI 1255882593

Payments from drug & device makers

$2,710in general payments, 2019–2025

Across 84 payments — averaging $32.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$405
  • AbbVie$362
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$340
  • Regeneron Healthcare Solutions, Inc.$250
  • Teva Pharmaceuticals USA, Inc.$220
  • Optinose US, Inc.$206
  • plus $927 from 18 others

What the payments were for

  • Food & beverage$2,59796%
  • Education$1134%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,710 in reported general payments places this provider in the 80th percentile of 8,062 physician assistant providers in Florida.

See all physician assistant providers in Florida

Medicare billing

Part B allowed, 2024
$4,039
Medicare patients
28
Services billed
319

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban81$52,674
XareltoRivaroxaban27$20,718
MyrbetriqMirabegron22$11,723
Breo ElliptaFluticasone/Vilanterol19$8,147
Metoprolol Succinate90$2,352
Gabapentin92$2,330
Pantoprazole Sodium117$2,021
Donepezil Hcl88$1,772
Dorzolamide-TimololDorzolamide/Timolol/Pf13$1,693
Levothyroxine Sodium100$1,430
Methenamine Hippurate15$1,420
Memantine Hcl49$1,412
Diltiazem 24hr Er (Cd)Diltiazem Hcl26$1,364
Midodrine Hcl15$1,260
Amlodipine Besylate120$1,223

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$166$20,71827 claims
GSKBreo Ellipta$60$8,14719 claims
Almatica Pharma LLCSertraline Hcl$52$73845 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,062 physician assistant providers in Florida.

Other physician assistant in Naples

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →